RS62236B1 - Rekombinantni dgkk gen za gensku terapiju fragilnog x sindroma - Google Patents
Rekombinantni dgkk gen za gensku terapiju fragilnog x sindromaInfo
- Publication number
- RS62236B1 RS62236B1 RS20211019A RSP20211019A RS62236B1 RS 62236 B1 RS62236 B1 RS 62236B1 RS 20211019 A RS20211019 A RS 20211019A RS P20211019 A RSP20211019 A RS P20211019A RS 62236 B1 RS62236 B1 RS 62236B1
- Authority
- RS
- Serbia
- Prior art keywords
- gene
- fragile
- recombinant
- dgkk
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01107—Diacylglycerol kinase (2.7.1.107)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306232.6A EP3299456A1 (en) | 2016-09-26 | 2016-09-26 | Recombinant dgkk gene for fragile x syndrome gene therapy |
PCT/EP2017/074387 WO2018055206A1 (en) | 2016-09-26 | 2017-09-26 | Recombinant dgkk gene for fragile x syndrome gene therapy |
EP17780349.1A EP3516052B1 (en) | 2016-09-26 | 2017-09-26 | Recombinant dgkk gene for fragile x syndrome gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
RS62236B1 true RS62236B1 (sr) | 2021-09-30 |
Family
ID=57130319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20211019A RS62236B1 (sr) | 2016-09-26 | 2017-09-26 | Rekombinantni dgkk gen za gensku terapiju fragilnog x sindroma |
Country Status (17)
Country | Link |
---|---|
US (2) | US11597936B2 (sr) |
EP (2) | EP3299456A1 (sr) |
JP (1) | JP7189131B2 (sr) |
CN (1) | CN110168082A (sr) |
BR (1) | BR112019005959A2 (sr) |
CA (1) | CA3077105C (sr) |
CY (1) | CY1124572T1 (sr) |
DK (1) | DK3516052T3 (sr) |
ES (1) | ES2883358T3 (sr) |
HR (1) | HRP20211256T1 (sr) |
HU (1) | HUE055699T2 (sr) |
LT (1) | LT3516052T (sr) |
PL (1) | PL3516052T3 (sr) |
PT (1) | PT3516052T (sr) |
RS (1) | RS62236B1 (sr) |
SI (1) | SI3516052T1 (sr) |
WO (1) | WO2018055206A1 (sr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019236949A1 (en) * | 2018-06-08 | 2019-12-12 | Avexis Inc. | Cell-based assay for measuring drug product potency |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003281515A1 (en) * | 2002-07-19 | 2004-02-09 | Cellzome Ag | Protein complexes of cellular networks underlying the development of cancer and other diseases |
WO2010094061A1 (en) * | 2009-02-17 | 2010-08-26 | Murdoch Childrens Research Institute | Assay for determining epigenetic profiles of markers of fragile x alleles |
EP2723902A4 (en) * | 2011-06-24 | 2015-02-18 | Murdoch Childrens Res Inst | TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND DISEASES |
AU2016324144B2 (en) * | 2015-09-17 | 2021-07-29 | University Of Massachusetts | Compositions and methods for modulating FMR1 expression |
-
2016
- 2016-09-26 EP EP16306232.6A patent/EP3299456A1/en not_active Withdrawn
-
2017
- 2017-09-26 PL PL17780349T patent/PL3516052T3/pl unknown
- 2017-09-26 CN CN201780072788.9A patent/CN110168082A/zh active Pending
- 2017-09-26 PT PT177803491T patent/PT3516052T/pt unknown
- 2017-09-26 BR BR112019005959A patent/BR112019005959A2/pt unknown
- 2017-09-26 RS RS20211019A patent/RS62236B1/sr unknown
- 2017-09-26 HR HRP20211256TT patent/HRP20211256T1/hr unknown
- 2017-09-26 US US16/336,488 patent/US11597936B2/en active Active
- 2017-09-26 JP JP2019516199A patent/JP7189131B2/ja active Active
- 2017-09-26 SI SI201730874T patent/SI3516052T1/sl unknown
- 2017-09-26 WO PCT/EP2017/074387 patent/WO2018055206A1/en active Application Filing
- 2017-09-26 HU HUE17780349A patent/HUE055699T2/hu unknown
- 2017-09-26 CA CA3077105A patent/CA3077105C/en active Active
- 2017-09-26 EP EP17780349.1A patent/EP3516052B1/en active Active
- 2017-09-26 ES ES17780349T patent/ES2883358T3/es active Active
- 2017-09-26 LT LTEP17780349.1T patent/LT3516052T/lt unknown
- 2017-09-26 DK DK17780349.1T patent/DK3516052T3/da active
-
2021
- 2021-08-19 CY CY20211100744T patent/CY1124572T1/el unknown
-
2023
- 2023-03-01 US US18/176,500 patent/US20230250404A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7189131B2 (ja) | 2022-12-13 |
WO2018055206A1 (en) | 2018-03-29 |
EP3516052A1 (en) | 2019-07-31 |
HUE055699T2 (hu) | 2021-12-28 |
BR112019005959A2 (pt) | 2019-06-18 |
CA3077105C (en) | 2024-01-09 |
US20230250404A1 (en) | 2023-08-10 |
ES2883358T3 (es) | 2021-12-07 |
HRP20211256T1 (hr) | 2022-01-07 |
CN110168082A (zh) | 2019-08-23 |
CY1124572T1 (el) | 2022-07-22 |
PT3516052T (pt) | 2021-08-30 |
SI3516052T1 (sl) | 2021-09-30 |
EP3516052B1 (en) | 2021-05-26 |
LT3516052T (lt) | 2021-09-10 |
US11597936B2 (en) | 2023-03-07 |
EP3299456A1 (en) | 2018-03-28 |
PL3516052T3 (pl) | 2021-11-29 |
DK3516052T3 (da) | 2021-08-23 |
JP2019532637A (ja) | 2019-11-14 |
US20190225950A1 (en) | 2019-07-25 |
CA3077105A1 (en) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804071B (en) | Recombinant zika vaccines | |
HK1248723B (zh) | 基因治療 | |
GB2562927B (en) | Single-flux-quantum probabilistic digitizer | |
HUE062186T2 (hu) | Módosított UBE3A gén az Angelman-szindróma génterápiás megközelítésére | |
IL268125A (en) | Pridopidine for the treatment of fragile x syndrome | |
HUE056570T2 (hu) | Génterápia | |
IL257500A (en) | Altered cullin1 gene | |
HUE057728T2 (hu) | Szubsztrátumhordozó | |
HK1247903A1 (zh) | 非接觸式主動控制傳送組件 | |
GB201707212D0 (en) | Gene therapy for ciliopathies | |
RS62236B1 (sr) | Rekombinantni dgkk gen za gensku terapiju fragilnog x sindroma | |
GB201701968D0 (en) | Gene therapy | |
DK3261679T3 (da) | Genterapi til synsforbedring | |
GB201517329D0 (en) | Diabetes gene therapy | |
IL263085A (en) | Garden healing | |
GB201704634D0 (en) | Gene therapy | |
GB201616821D0 (en) | Gene therapy | |
GB201612105D0 (en) | Gene therapy | |
GB201612104D0 (en) | Gene therapy | |
SG10201912076UA (en) | Gene therapy composition | |
GB201507125D0 (en) | Gene delivery | |
AU2015901161A0 (en) | Enhanced recombinant protein expression | |
AU2014904326A0 (en) | Interferon alpha 2b variants |